Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,144 public trials 2,036 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, not recruiting

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT05050097

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama Birmingham Birmingham, Alabama, United States
  • University of California San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Emory University Atlanta, Georgia, United States
View all 31 locations
View Trial Details
Active, not recruiting

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT04722146

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of California San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Winship Cancer Institute Emory University Atlanta, Georgia, United States
View all 27 locations
View Trial Details
Active, not recruiting

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

NCT06139406

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • Austin Hospital Heidelberg, Australia
  • The Alfred Hospital Melbourne, Australia
  • Linear Clinical Research Ltd Nedlands, Australia
  • Scientia Clinical Research Randwick, Australia
View Trial Details
Active, not recruiting

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

NCT03701282

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 865 locations
View Trial Details
Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Lymphoma, +138 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Thomas Hospital Fairhope, Alabama, United States
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
View all 1410 locations
View Trial Details
Active, not recruiting

A Study of Daratumumab

NCT05438043

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Miami Sylvester Cancer Center Miami, Florida, United States
  • Emory University Atlanta, Georgia, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
  • Barnes-jewish Hospital St Louis, Missouri, United States
View all 92 locations
View Trial Details
Active, not recruiting

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05421663

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • City of Hope Duarte, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • University of Iowa Hospital and Clinics Iowa City, Iowa, United States
  • University of Kentucky Medical Center Lexington, Kentucky, United States
View all 32 locations
View Trial Details
Active, not recruiting

A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

NCT06660563

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • Concord Hospital Concord, Australia
  • St Vincents Hospital Melbourne Fitzroy, Australia
  • Macquarie University Hospital North Ryde, Australia
  • Hosp Univ Vall D Hebron Barcelona, Spain
View Trial Details
Active, not recruiting

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Cleveland Clinic Florida Weston, Florida, United States
  • Augusta University- Georgia Cancer Center Augusta, Georgia, United States
View all 53 locations
View Trial Details

Related conditions